Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Novel Drugs Show Promise in NSCLC

January 14th 2013

An ever-deeper understanding of the biology that drives NSCLC is sparking new treatment paradigms that include selecting targeted drugs based on patients' biomarkers.

What is the New Lung Cancer Staging System?

January 12th 2013

The 7th edition TNM staging system for NSCLC is an exciting accomplishment, and will help the clinician to better understand the outcomes of lung cancer and offers an exciting advance to our specialty.

PointBreak Trial Misses Goals but Yields Clues for Maintenance Therapy

January 11th 2013

Despite missing its main goals, the PointBreak trial did provide guidance about how best to structure maintenance therapy in NSCLC, and it proved that an option besides paclitaxel is available.

Introducing the UC Davis Lung Cancer Chat Room

January 10th 2013

The UC Davis Lung Cancer Chat Room is an interactive meeting of learning and support for patients, families, friends and caregivers affected by lung cancer.

Dr. Mark Kris on Performance Status in Lung Cancer

January 9th 2013

Mark G. Kris, MD, chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center, discusses the importance of accurately determining a patient's performance status.

Special Populations in Lung Cancer Explored

January 8th 2013

PS2 patients in focus at the 7th Annual New York Lung Cancer Symposium, hosted by Physicians' Education Resource, that took place in New York City.

Dr. Gettinger on Lung Cancer Immunotherapies

January 8th 2013

Scott Gettinger, MD, associate professor of medicine (medical oncology), Yale School of Medicine, explains the development of immunotherapies in lung cancer.

Mark G. Kris, MD, Discusses Emerging Targets and Treatments for Lung Cancer

January 4th 2013

Mark G. Kris, MD, offers insight into NSCLC related topics, including emerging therapeutic targets, the optimal application of TKIs, strategies for patients with poor performance status, maintenance therapies, and the treatment pipeline.

Local Ablative Therapy Might Extend TKI Benefit in NSCLC

December 24th 2012

Local ablative therapy plus continuation on the same tyrosine kinase inhibitor could be utilized as a treatment alternative in metastatic non-small cell lung cancer.

Novel Cancer Vaccine Fails To Significantly Improve Overall Survival in Lung Cancer

December 21st 2012

Results of a large phase III trial testing the efficacy of the investigational vaccine L-BLP25 in patients with advanced lung cancer found that the vaccine failed to show a statistically significant improvement in overall survival

Dr. Kris on Dacomitinib in EGFR-Positive Lung Cancer

December 12th 2012

Mark G. Kris, MD, from Memorial Sloan-Kettering Cancer Center, discusses the administration of dacomitinib for patient with EGFR-positive lung cancer.

Dr. Gettinger on PD-1 Inhibitor BMS-936558 in NSCLC

December 11th 2012

Scott Gettinger, MD, from the Yale School of Medicine, discusses updated results from a phase I trial that examined the novel immunotherapy BMS-936558 in patients with NSCLC and other solid tumors.

EGFR Mutation Status Might Predict Sorafenib Benefit in NSCLC

November 30th 2012

Results of the phase III MISSION trial showed that third- or fourth-line treatment with sorafenib did not improve overall survival in patients with advanced non–small cell lung cancer.

Addition of Motesanib to Chemotherapy Offers No Benefit for Patients With Non-Small Cell Lung Cancer

November 27th 2012

Motesanib combined with carboplatin/paclitaxel does not significantly improve OS versus carboplatin/ paclitaxel alone in patients with advanced nonsquamous non–small cell lung cancer, according to the results of the phase III MONET1 study.

FDA Grants Orphan Drug Status to Amatuximab for Malignant Pleural Mesothelioma

November 12th 2012

Amatuximab has received orphan drug status from the FDA to treat patients with malignant pleural mesothelioma, the most common form of mesothelioma.

Dr. Kris Discusses Crizotinib in ALK-Positive Lung Cancer

November 2nd 2012

Mark G. Kris, MD, from Memorial Sloan-Kettering Cancer Center, discusses the results of a phase III trial that studied the use of crizotinib in patients with advanced ALK-positive lung cancer.

No Survival Benefit Found When Adding Bevacizumab to Gemcitabine/Cisplatin in Malignant Mesothelioma

October 31st 2012

The addition of bevacizumab to gemcitabine/cisplatin does not significantly improve progression-free survival or overall survival in patients with previously untreated, unresectable malignant mesothelioma.

Dr. Gandara Describes Exciting Lung Cancer Research

October 24th 2012

David R. Gandara, MD, University of California, Davis Comprehensive Cancer Center, provides his opinion on some of the most exciting research currently taking place for patients with NSCLC.

Dacomitinib Bests Erlotinib in Advanced Non-Small Cell Lung Cancer

October 23rd 2012

Treatment with the investigational agent dacomitinib improved PFS when compared with erlotinib in patients with non–small cell lung cancer experiencing progression during chemotherapy.

7th New York Lung Cancer Symposium Provides Overview

October 22nd 2012

Targeted therapies, personalized medicine, and best management approaches will be the central topics of discussion at the 7th New York Lung Cancer Symposium.

NEXT PAGE
PREVIOUS PAGE